Catalent, Inc. (NYSE:CTLT) Given Consensus Rating of “Hold” by Brokerages

Catalent, Inc. (NYSE:CTLTGet Free Report) has been given a consensus recommendation of “Hold” by the thirteen analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $52.46.

Several equities research analysts recently weighed in on CTLT shares. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 price target (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, November 14th. Stephens reaffirmed an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, February 6th. Robert W. Baird raised shares of Catalent from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $45.00 to $53.00 in a research report on Thursday, November 16th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $63.50 target price (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th.

Get Our Latest Report on CTLT

Catalent Price Performance

CTLT stock opened at $56.99 on Tuesday. The firm has a 50 day moving average price of $47.34 and a 200-day moving average price of $44.83. Catalent has a 52-week low of $31.45 and a 52-week high of $74.49. The firm has a market capitalization of $10.29 billion, a price-to-earnings ratio of -8.38, a PEG ratio of 3.03 and a beta of 1.20. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.47.

Catalent (NYSE:CTLTGet Free Report) last announced its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. Catalent’s revenue was down 10.2% on a year-over-year basis. During the same period last year, the business earned $0.62 EPS. Equities research analysts forecast that Catalent will post 0.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Cetera Advisor Networks LLC lifted its stake in shares of Catalent by 7.1% during the 1st quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock valued at $217,000 after buying an additional 130 shares in the last quarter. Mackay Shields LLC lifted its stake in shares of Catalent by 0.6% during the 1st quarter. Mackay Shields LLC now owns 25,749 shares of the company’s stock valued at $2,856,000 after buying an additional 149 shares in the last quarter. Wetherby Asset Management Inc. lifted its stake in Catalent by 5.1% in the 1st quarter. Wetherby Asset Management Inc. now owns 5,023 shares of the company’s stock worth $557,000 after purchasing an additional 243 shares in the last quarter. Bessemer Group Inc. lifted its stake in Catalent by 3.8% in the 2nd quarter. Bessemer Group Inc. now owns 6,801 shares of the company’s stock worth $295,000 after purchasing an additional 252 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV lifted its stake in Catalent by 1.2% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 21,164 shares of the company’s stock worth $953,000 after purchasing an additional 252 shares in the last quarter.

Catalent Company Profile

(Get Free Report

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Further Reading

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.